LTFS
CSBR icon

Ladenburg Thalmann Financial Services’s Champions Oncology CSBR Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$0 Sell
12
-4
-25% -$25 ﹤0.01% 5347
2019
Q3 		$0 Hold
16
– – ﹤0.01% 5296
2019
Q2 		$0 Buy
+16
New +$140 ﹤0.01% 5285
2019
Q1 		– Sell
-971
Closed -$8K – 5220
2018
Q4 		$8K Sell
971
-662
-41% -$7.6K ﹤0.01% 4390
2018
Q3 		$29K Buy
+1,633
New +$14.5K ﹤0.01% 3657

Other funds holding CSBR

BPI
Battery Partners IX Boston, Massachusetts $22.4M AUM 27.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ladenburg Thalmann Financial Services's CSBR Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its Champions Oncology (CSBR) stake by 25% in Q4 2019, selling an estimated $25 and leaving 12 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5347.

Ladenburg Thalmann Financial Services first reported a position in CSBR in Q3 2018 and has held it in 5 quarters since. The position peaked at $29K in Q3 2018. 32 funds tracked by Wall St. Rank hold CSBR as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 12 shares of Champions Oncology worth $0 as of Q4 2019.
  • Ladenburg Thalmann Financial Services sold 4 Champions Oncology shares in Q4 2019, an estimated $25.
  • Champions Oncology made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5347 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Champions Oncology in Q3 2018 and has held it in 5 quarters since.
  • Ladenburg Thalmann Financial Services's Champions Oncology position peaked at $29K in Q3 2018.
  • 32 funds tracked by Wall St. Rank held Champions Oncology as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.